Instructions on whether deuterated colexitinib (decavatinib) requires long-term or lifelong use

Deucravacitinib is a selective Tyk2 inhibitor primarily used to treat patients with moderate to severe plaque psoriasis. It regulates the downstream inflammatory response of IL-23, IL-12 and IFN signals by specifically inhibiting the Tyk2 signaling pathway, thereby alleviating psoriasis-related skin damage and symptoms. Compared with traditional immunosuppressants, decavatinib is convenient to take, highly targeted, and has relatively controllable side effects. However, psoriasis itself is a chronic and easily relapsed disease, so the medication strategy needs to be comprehensively judged based on the course of the disease and the patient's individual situation.

For most patients, decavatinib requires long-term treatment to maintain efficacy. Clinical studies have shown that the rash may recur within weeks to months after stopping the drug. This is because the inflammatory network in the pathogenesis of psoriasis is still active, and the drug cannot continue to suppress the Tyk2-mediated inflammatory response after the drug is stopped. Therefore, in order to maintain control of skin symptoms and improve quality of life, patients usually need to continue taking it under the guidance of a doctor until their condition is stable and the feasibility of gradual reduction can be evaluated.

Whether lifelong use is required depends on the patient's condition and individual response. Some patients can achieve stable symptoms after long-term treatment, and doctors may try to intermittently reduce the dosage or use the medication intermittently to reduce drug exposure and the risk of potential side effects; however, for patients with recurrent or severe relapses, long-term or even continuous use may be more conducive to controlling the progression of psoriasis. Patients need regular follow-up visits to assess skin symptoms and quality of life, and develop an individualized maintenance plan based on hematology and liver and kidney function monitoring.

In long-term medication management, attention should be paid to safety and lifestyle. Common adverse reactions of decavatinib include upper respiratory tract infection, headache, fatigue and mild liver enzyme elevation. Patients should regularly monitor liver function and pay attention to infection protection. During long-term medication, rationally arranging work and rest, maintaining skin care and eating a healthy diet will help improve tolerance to the effects. Generally speaking, decavatinib often needs to be taken for a long time in the treatment of psoriasis, but whether to take it for life requires a combination of disease assessment and doctor's guidance, and an individualized plan to achieve the best balance between efficacy and safety.

Reference materials:https://www.drugs.com/